Q-State Biosciences joins the HESI Cardiac Safety Technical Committee (CSC) and is also an official member of the Comprehensive In Vitro Proarrhythmia Assay (CiPA) Initiative.  

 

The CiPA Initiative is driven by HESI, the US Food & Drug Administration (FDA) and the Safety Pharmacology Society (SPS). Its goal is the development of tools for the early prediction of cardiac arrhythmias as a side effect of pharmaceuticals.  

 

Q-State Biosciences is participating in a pilot study to explore the role of stem cell cardiomyocytes in CiPA. Q-State Biosciences will apply its proprietary all optical electrophysiology platform in hESC- or iPSC-derived cardiomyocytes for early compound screening.

 

 

For more information, please visit: